Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to MYPI20063260priorityCriticalpatent/MY143584A/en
Publication of MY143584ApublicationCriticalpatent/MY143584A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
THE PRESENT INVENTION RELATES TO CERTAIN NOVEL COMPOUNDS OF THE FORMULA I TO PROCESSES FOR PREPARING SUCH COMPOUNDS, TO THEIR THE UTILITY IN MODULATION OF NUCLEAR HORMONE RECEPTORS LIVER X RECEPTOR (LXR) Α (NR1H3) AND/OR Β (NR1H2) AND IN TREATING AND/OR PREVENTING CLINICAL CONDITIONS INCLUDING CARDIOVASCULAR DISEASES SUCH AS ATHEROSCLEROSIS; INFLAMMATORY DISEASES, ALZHEIMER’S DISEASE, LIPID DISORDERS (DYSLIPIDEMIAS) WHETHER OR NOT ASSOCIATED WITH INSULIN RESISTANCE, TYPE 2 DIABETES AND OTHER MANIFESTATIONS OF THE METABOLIC SYNDROME, TO METHODS FOR THEIR THERAPEUTIC USE AND TO PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MYPI200632602006-07-072006-07-07Non-anilinic derivatives of isothiazol-3(2h)-one 1, 1-dioxides as liver x receptor modulators
MY143584A
(en)
compound, pharmaceutical composition, use of a compound, and methods of preparing a pharmaceutical composition, inhibiting the function of 11betahydroxysteroid dehydrogenase type 1 and treating or preventing a disorder